Cancer patients, even with the same cancer diagnose, have different individual response to cancer drugs. By treating patient own live cancer sample with a vast amount of cancer drugs we identify the right drug in the right dose to the right patient. Just as important, ineffective treatment causing only adverse effects and reduced quality of life is avoided. Seald is now raising funds to develop the method in our clinical study approved by the The Regional Committees for Medical and Health Ethics (REK).
Our working model is bile duct cancer. The bile ducts are small hollow tubes that connects the liver to the small intestine. The ducts transport the bile fluid to the intestine, where the bile is involved in the digestive system. The bile fluid is stored in the gall bladder which is part of the system. Bile duct cancer is a rare and very deadly form of cancer, with a high unmet medical need on a global basis. Bile duct cancer is the second most common cancer in the liver, afflicting three per cent of people with cancer of the digestive system. The occurrence is raising of unknown causes, and due to international differences bile duct cancer is considered a major cancer type of the digestive system.
At present, the five-year survival rate is two to five per cent, the mean life expectancy is only 11,5 months on standard treatment, and there is no known cure. A small group of the patients are eligible for surgery, but of these 50% relapse.
Sealds pre-clinical studies have identified new and unexpected beneficial effect of drugs not previously used on bile duct cancer.
Our approach is based on the concept of personalised medicine where the treatment is tailored to the individual patient. We do this on the basis of cancer drug sensitivity screening (CDSS) on the patients’ own living cancer cells. In addition, we also investigate the tumour for specific gene alteration and biomarkers.
Utilising an entirely new, innovative approach and the latest methods, SEALD AS aspires to find the right treatment for the individual patient by combining live approach, molecular biomarkers, DNA sequencing, ex vivo drug sensitivity analysis and live xenograft animal models.[/vc_column_text][/vc_column][/vc_row]